CAR T Cells for Mantle Cell Lymphoma: Is it Time to Reshuffle the Deck? uri icon

Overview

abstract

  • In the New England Journal of Medicine, Wang et al. report favorable ZUMA-2 trial results of CAR T cells for patients with relapsed and refractory mantle cell lymphoma following prior failed Bruton's tyrosine kinase inhibitor therapy, with an overall response rate of 93% and an expected safety profile.

publication date

  • June 8, 2020

Research

keywords

  • Lymphoma, Mantle-Cell

Identity

Scopus Document Identifier

  • 85085756185

Digital Object Identifier (DOI)

  • 10.1016/j.ccell.2020.05.015

PubMed ID

  • 32516587

Additional Document Info

volume

  • 37

issue

  • 6